Detection of Chlamydia trachomatis by PCR with reactive arthritis

Chlamydia trachomatis has been shown to induce reactive arthritis in people, especially after sexually acquired genitourinary infection. To determine the connection between Chlamydia trachomatis with reactive arthritis, in this study we examined antigen Chlamydia trachomatis lipopolysarcaride. Antibody IgG, and DNA of chlamydia trachomatis were investigated in samples (urine, serum, and synovial fluid) from 52 patients were diagnosed and treated in Rheumatology Department, Bach Mai Hospital from August 2001 to August 2003. As results we found that 38.5% urine samples positve with antigen LPS. Antibody IgG positive in 44.2% of serum samples and in 34.6% of synovial fluid samples. Special DNA of Chlamydia trachomatis was detected in 53.2% of synovial fluid samples and in 42.2% of urine samples positive. This results will contribute to determine the role of DNA-Chlamydia trachomatis in reactive arthritis diagnosis.

The infection rates of HBV, HCV, HIV in blood donors at the National Institute of Hematology and Blood Transfusion from 1/2003 to 6/2005

We conducted data analysis on infection rates of hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodifficiency virus (HIV) in paid blood donors and volunteers at National Institute of Hematology and Blood Transfusion from 2003 to June 2005. The results showed that by using HBsAg quick test for pre-screening donors, the number of blood units infected with HBV decreased considerably from 7.13% in 2003 to 2.89% in 2004 then to 1.2% in 2005. The highest reduction was in the volunteer group. The prevalence of HCV and HIV in the donors was still low and consistent with those of previous years (HCV = 1% and HIV = 0.1%). Finally, the rate of HCV co-infection in HIV-positive donors was quite common (69%) and higher than the rate of HBV co-infection in HIV positive donors (1.92%).

The rate of p53 gene carrier in the high risk group of exposure to dioxine

Diseases caused by dioxine include mainly various types of cancers and p53 is one important gene in carcinogenesis-suppressing gene family. Objectives: This research's goal is detecting p53 gene's ratio in the high risk group of exposure to dioxine. Methods: In this study we detected p53 ratio in 50 cases in the group of high risk of exposure to dioxine and the control group of 30 cases. Gene p53 was detected by PCR technique. Results: The study showed that in the control group (no exposure to dioxine), p53 prevalence is 100% compared with 82% in high - risk group (p <0.05). Conclusions: p53 was not detected in 18% of the group of high risk exposure to dioxin, suggesting that there were serious damages in p53 gene (deletion...)

HNA frequencies in the Kinh ethnic of Vietnam population, determined by polymerase chain reaction with sequence-specific primers

The human neutrophil antigens (HNA) are often targets of granulocyte antibodies causing immune neutropenia. Typing for HNA is useful in a veriety of clinical situations. The author developed a method for genotyping for HNA-1 by means of the PCR ampification with sequence specific primer (PCR-SSP) technique. The typing results were available within 5 hours each time for one blood sample tested. In 61 granulocytes samples, the gen frequencies were 64.7% for HNA-1a and 35.2% for HNA-1b. The HNA-1a gene is more frequent in the Kinh population than the HNA-1b

Phenotyping human platelet antigens of the Kinh population in the centre, Vietnam

Located on the platelet membrane surface, human platelet specific antigens (HPAs) are related to alloimmune thrombocytopenic syndromes. The frequencies of HPA genes vary between different populations. In this study, the author initially identified HPA gene frequencies of Kinh population which are living in the Centre of Vietnam by polymerase chain reaction with specific sequence primers (PCR-SSP). The frequencies observed are following: 0.977, 0.023, 0.000 for HPA-1a/a, HPA-1b/b; 0.827, 0.161, 0.011 for HPA-2a/a, HPA-2a/b, HPA-2b/b; 0.276, 0.552, 0.173 for HPA-3a/a, HPA-3a/b, HPA-3b/b; 0.920, 0.080, 0.000 for HPA-5a/a, HPA-5a/b, HPA-5b/b. respectively. For HPA-4, all 87 donor samples presented HPA-4a/a